What are OS Therapies's total assets?

OS Therapies (OSTX) holds $7.3M in total assets, up 71.8% year over year.

How much debt does OS Therapies have?

OS Therapies carries $20.0M in total debt against -$10.8M of shareholders' equity, a debt-to-equity ratio of -1.85.

How much cash does OS Therapies have?

OS Therapies holds $917.6K in cash and equivalents.

Can OS Therapies cover its short-term obligations?

Its current ratio is 0.05 — current liabilities exceed current assets.

Where does OS Therapies's balance sheet data come from?

Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

OS Therapies OSTX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$917.55K+240%	$269.83K-85.6%	$1.88M-33.0%	$2.8M-5.7%	$2.97M-46.3%
Prepaid expenses and other current assets	——	$63.08K—	——	——	——
Total current assets	$917.55K+176%	$332.91K-85.7%	$2.32M-34.7%	$3.55M-13.2%	$4.1M-26.0%
Property and equipment, net	$1.8K-27.9%	$2.49K-21.8%	$3.19K-17.9%	$3.88K-15.2%	$4.58K—
Intangible assets, net	$6.38M—	——	——	——	——
Deferred tax assets	——	——	——	——	——
Other non-current assets	$6.38M-1.9%	$6.5M—	——	——	——
Total noncurrent assets	——	——	——	——	——
Total assets	$7.3M+6.7%	$6.84M-23.6%	$8.95M-13.2%	$10.31M+143%	$4.25M-23.3%
Accrued expenses	$1.38M0.0%	$1.38M+249%	$395.45K+4.0%	$380.31K+4.4%	$364.41K-30.1%
Current portion of long-term debt	——	——	——	——	——
Dividends payable	$375K0.0%	$375K0.0%	$375K0.0%	$375K0.0%	$375K0.0%
Total current liabilities	$16.95M+44.1%	$11.76M+184%	$4.15M+19.9%	$3.46M-2.2%	$3.54M-23.6%
Total noncurrent liabilities	$100K0.0%	$100K0.0%	$100K0.0%	$100K0.0%	$100K0.0%
Total liabilities	$17.05M+43.7%	$11.86M+179%	$4.25M+19.3%	$3.56M-2.2%	$3.64M-23.1%
Common stock	150M0.0%	150M+200%	50M0.0%	50M0.0%	50M-66.7%
Additional paid-in capital	$66.72M+9.3%	$61.05M+6.5%	$57.33M+10.8%	$51.76M+35.8%	$38.1M+8.4%
Retained earnings	-$77.58M-15.5%	-$67.19M-25.1%	-$53.73M-14.7%	-$46.85M-10.7%	-$42.31M-10.1%
Total stockholders' equity	-$10.82M-77.6%	-$6.1M-268%	$3.64M-26.4%	$4.94M+218%	-$4.19M-28.2%
Total liabilities and stockholders' equity	$7.3M+6.7%	$6.84M-23.6%	$8.95M-13.2%	$10.31M+143%	$4.25M-23.3%
Alternative Investments Fair Value	——	——	——	——	——
Deposits on Licenses	$6.38M-1.9%	$6.5M—	——	——	——
Deferred Tax Assets - Tax Credit Carryforwards	——	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	$496.97K—	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	$4.02M—	——	——	——	——
Intangible assets — net	$6.38M—	——	——	——	——
Other Investments	——	——	——	——	——
Tax Credit Carryforward Valuation Allowance	——	——	——	——	——
Accounts Payable - Other Current	$70—	$0-100%	$15.93K-17.8%	$19.37K—	$0-100%
Convertible Debt - Current	$1.34M—	——	——	——	——
Accounts payable and other current liabilities (Note 11)	——	——	——	——	——
Accrued Payroll And Payroll Taxes Related Party	——	——	——	——	——
Total debt	——	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	39.3M+5.8%	37.1M+11.6%	33.3M+12.2%	29.7M+39.0%	21.3M+2.3%
Convertible Preferred Stock Authorized Shares	5M0.0%	5M0.0%	5M0.0%	5M0.0%	5M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Additional paid-in capital	$66.72M+9.3%	$61.05M+6.5%	$57.33M—	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$39.28K+5.8%	$37.11K+11.6%	$33.27K+12.2%	$29.67K+39.0%	$21.35K+2.3%
Number of Exercisable Options	——	——	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	8.4M+23.4%	6.8M+136%	2.9M—	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Share Price	——	——	——	——	——
Temporary Equity Attributable to Parent	$1.07M0.0%	$1.07M0.0%	$1.07M—	——	——
Temporary Equity Excluding Additional Paid-in Capital	$1.07M0.0%	$1.07M0.0%	$1.07M—	——	——
Weighted Average Exercise Price of Outstanding Options	$1.74-4.9%	$1.83-1.6%	$1.86—	——	——
Employee payroll tax withheld on employee stock transactions	——	——	——	——	——
Accrued Payroll Taxes Current And Noncurrent	——	——	——	——	$23.64K—
Cash FDIC Insured Amount	$250K0.0%	$250K—	——	——	——
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1	——	——	——	——	——
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right	——	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$150M0.0%	$150M+200%	$50M0.0%	$50M0.0%	$50M-66.7%
Common stock, shares issued (in shares)	$39.28M+5.8%	$37.11M+11.6%	$33.27M+12.2%	$29.66M+39.0%	$21.35M+2.3%
Common Stock, Shares, Outstanding	$39.28M+5.8%	$37.11M+11.6%	$33.27M+12.2%	$29.66M+39.0%	$21.35M+2.3%
Conversion Price Percentage	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	——	——	——	——
R&D credit carryforward	——	——	——	——	——
Cost not yet recognized	——	——	——	——	——
2028	$496.97K—	——	——	——	——
2030	$496.97K—	——	——	——	——
2031	——	——	——	——	——
Remainder of 2026	——	——	——	——	——
2027	$496.97K—	——	——	——	——
2029	$496.97K—	——	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Five	$4.02M—	——	——	——	——
Grants receivable	——	——	——	——	——
Interest Bearing Domestic Deposit Money Market	$10K0.0%	$10K0.0%	$10K—	——	——
2027	——	——	——	——	——
Number Of Tranches	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Prepaid expenses	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$8.36M+23.4%	$6.77M+136%	$2.87M—	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$1.74-4.9%	$1.83-1.6%	$1.86—	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Share price (in dollars per share)	——	——	——	——	——
Tax Credit Carryforward Valuation Allowance	——	——	——	——	——
TEDCO Grant Non Current	$100K0.0%	$100K0.0%	$100K0.0%	$100K—	——
Temporary Equity Liquidation Preference	$2.5M0.0%	$2.5M0.0%	$2.5M0.0%	$2.5M0.0%	$2.5M0.0%
Temporary Equity Par Or Stated Value Per Share	——	——	——	——	——
Temporary Equity Shares Authorized	——	——	——	——	——
Temporary Equity Shares Issued	——	——	——	——	——
Temporary Equity Shares Outstanding	——	——	——	——	——
Redeemable convertible preferred stock, par value ($ per share)	$1.07M0.0%	$1.07M0.0%	$1.07M—	——	——
Value added tax receivable	——	——	——	——	——
Warrants And Rights Outstanding	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are OS Therapies's total assets?: OS Therapies (OSTX) holds $7.3M in total assets, up 71.8% year over year.
How much debt does OS Therapies have?: OS Therapies carries $20.0M in total debt against -$10.8M of shareholders' equity, a debt-to-equity ratio of -1.85.
How much cash does OS Therapies have?: OS Therapies holds $917.6K in cash and equivalents.
Can OS Therapies cover its short-term obligations?: Its current ratio is 0.05 — current liabilities exceed current assets.
Where does OS Therapies's balance sheet data come from?: Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.